InsiderTrades.com logo

CMMB Insider Trading

Insider Ownership Percentage: 11.91%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $6,516.40

Chemomab Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Chemomab Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Chemomab Therapeutics Share Price & Price History

Current Price: $1.39
Price Change: ▲ Price Increase of +0.02 (1.46%)
As of 10/8/2026 04:00 PM ET

This chart shows the closing price history over time for CMMB up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Chemomab Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/28/2026Neil Harris CohenDirectorSell1,000$2.80$2,800.0033,000View SEC Filing Icon  
8/27/2026Neil Harris CohenDirectorSell1,304$2.85$3,716.4034,000View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Chemomab Therapeutics (NASDAQ:CMMB)

46.05% of Chemomab Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CMMB by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Chemomab Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
4/20/2026Kestra Private Wealth Services LLC61,710$97K0.0%+19.3%0.858%Search for SEC Filing on Google Icon
2/18/2026XTX Topco Ltd19,013$31K0.0%N/A0.309%Search for SEC Filing on Google Icon
2/17/2026ADAR1 Capital Management LLC80,000$0.13M0.0%N/A1.299%Search for SEC Filing on Google Icon
1/29/2026Kestra Private Wealth Services LLC51,710$85K0.0%N/A0.839%Search for SEC Filing on Google Icon
11/6/2025Rhumbline Advisers9,505$25K0.0%-76.2%0.184%Search for SEC Filing on Google Icon
8/14/2025Orbimed Advisors LLC940,990$1.09M0.0%-46.0%4.990%Search for SEC Filing on Google Icon
5/12/2025Virtu Financial LLC30,803$34K0.0%+113.2%0.215%Search for SEC Filing on Google Icon
4/28/2025Yelin Lapidot Holdings Management Ltd.578,291$0.63M0.1%-22.3%4.027%Search for SEC Filing on Google Icon
2/13/2025XTX Topco Ltd24,929$45K0.0%+63.8%0.174%Search for SEC Filing on Google Icon
2/11/2025Virtu Financial LLC14,445$26K0.0%N/A0.101%Search for SEC Filing on Google Icon
2/5/2025Yelin Lapidot Holdings Management Ltd.744,127$1.35M0.2%-8.1%5.182%Search for SEC Filing on Google Icon
11/15/2024Sphera Funds Management LTD.1,214,575$1.91M0.3%N/A8.458%Search for SEC Filing on Google Icon
2/1/2023Kestra Private Wealth Services LLC31,241$100K0.0%N/A0.271%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Chemomab Therapeutics logo
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Read More on Chemomab Therapeutics

Today's Range

Now: $1.39
Low: $1.36
High: $1.44

50 Day Range

MA: $2.14
Low: $1.19
High: $2.83

52 Week Range

Now: $1.39
Low: $1.05
High: $3.55

Volume

20,597 shs

Average Volume

150,566 shs

Market Capitalization

$10.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.74

Who are the company insiders with the largest holdings of Chemomab Therapeutics?

Chemomab Therapeutics' top insider investors include:
  1. Israel Gp Ltd Orbimed (Major Shareholder)
  2. George Adi Mor (Insider)
  3. Neil Harris Cohen (Director)
  4. Donald Marvin (CFO)
  5. Dale R Pfost (CEO)
  6. Joel Michael Maryles (Director)
Learn More about top insider investors at Chemomab Therapeutics.

Chemomab Therapeutics Active Insiders

Neil Harris Cohen
Neil Harris Cohen
Director
2 recent trades